Ilacqua to Lead Oncology Monitor

Synovate Healthcare has appointed Jacquelyn S. Ilacqua as Head of its pioneering cancer study, the Global Tandem Oncology Monitor.

Ilacqua, who will continue to be based in the US, has been with the company and its predecessors since 1990 and has worked in a variety of roles, beginning as a medical interviewer and recently becoming Senior VP leading Synovate's custom pharmaceutical research division. Most recently she led the Tandem Cancer Monitor and associated business within the US. She has created some of the more popular proprietary methodologies for the specialist division, including OptiVision, a clinical pathways study, and PharmaVision, a model to determine barriers to expanded usage.

Synovate Healthcare CEO Michael Spedding describes Ilacqua as 'the natural choice' to maintain the division's progress towards building of its global position and expertise whilst ensuring local relevance.

The Global Tandem Oncology Monitor covers the US, Europe and Japan, and boasts the only 'robust and representative sample... utilizing a tried and true projection methodology'. Uses include tracking usage and market share, reviewing off-label usage, determining changes in treatment, tracking the launch of new oncology products and understanding the patient types most likely to receive certain drugs or regimens.

The company is on the web at www.synovate.com/healthcare

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• All news